Investment Opportunity

Early Cancer Detection Tech with Multi-Billion-Dollar Potential

Mainz Biomed | Listed on: NASDAQ:MYNZ

Mainz BioMed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. Clinical laboratory tests save costs and lives by enabling early detection and prevention of disease. At its center are genetic and genomic tests that identify the unique genetic profile of individual patients or their disease and allow physicians to tailor treatment to those unique characteristics.

Why You Should Consider Investing

  • Determined to succeed

    Mainz Biomed aims to become a leader in the multi-billion-dollar colorectal cancer diagnostics market.

  • Huge potential to lead the market

    ColoAlert holds potential as a blockbuster early detection test for colorectal cancer.

  • Primed for growth

    This is Europe's answer to Exact Sciences' (~$16 billion market cap) ColoGuard product.

  • Perfect time to invest

    Designed for profitability, rapid commercial uptake, and broad consumer acceptance.

  • Securely protected intellectual property

    Mainz BioMed protects its intellectual property through trade secrets to control all critical reagents, processes and formulations.

  • Developing new technologies

    Mainz BioMed is developing proprietary genetic testing methods for pancreatic cancer.

For a deep dive into Mainz BioMed's exciting trajectory in this worthwhile space, download the corporate deck.

Find out more

Biotech Breakout Story

Cancer testing stock set for prime time in US market

Mainz BioMed (NASDAQ: MYNZ) is a cancer-fighting stock you will not want to miss.

It presents an incredibly unique opportunity to participate in a blockbuster product in the fight against colorectal cancer.

Better still, it’s already approved for use in Europe and is making its way to North America.

According to the World Cancer Research Fund, colorectal cancer is the third most common cancer globally. It’s also the second leading cause of cancer death in the United States [1].

However, it doesn’t need to stay that way. Colorectal cancer is highly preventable. Indeed, early detection results in survival rates exceeding 90%! [2]

Mainz BioMed’s ColoAlert is a colorectal cancer screening testing kit for at-home use - it’s also a multi-billion-dollar market opportunity.

ColoAlertWith a proven product ready to roll out to the masses, Mainz BioMed could well be on to an absolute winner.

Revenues secured, ready to expand

Mainz BioMed’s commercialization strategy is straightforward.

ColoAlert has already been approved for sale in Europe, meaning the company already has established relationships with European distributors that could easily make for a smooth transition into other markets.

And with this setup established, Mainz BioMed is in a prime position to capitalize on smarter distribution and increased profit margins as it prepares to enter the lucrative US market.

FDA clinical study and submission process is set to be launched in Q1 2022.

After that, Mainz BioMed plans to leverage a decentralized laboratory business model to expand its distribution potential with regional and large national laboratory service providers in order to better market ColoAlert.

In addition to ColoAlert, Mainz BioMed is also in the early stages of developing a novel early detection pancreatic cancer screening test.

Decentralized business strategy

Mainz BioMed is looking at several financial advantages in adopting this decentralized strategy.

By selling ColoAlert directly to regional and national laboratory service providers across the USA (such as Quest Diagnostics or Lab Corp, etc.), its profit margins will likely exceed its competitors.

In particular, this gives it an advantage over Exact Sciences, which performs its ColoGuard analysis at its central laboratory.

Patients in the EU currently receive a simple ColoAlert kit that includes instructions, two stool collectors and shipping instructions to return the kit through regular mail to their local lab for testing and results.

Using this method, ColoAlert is designed for profitability, rapid commercial uptake, and broader consumer acceptance.

That’s because large labs are incentivized to support sales and marketing efforts to physicians and customers. As a result, there's a good chance ColoAlert use will eventually spread right acros sthe market.

One reason to get excited about this stock is that ColoAlert is less expensive and easier to administer than ColoGuard, more accurate than the standard Fecal Immunochemical Test (FIT) [3], and much, much less invasive than a colonoscopy.

[1] https://www.wcrf.org/dietandcancer/colorectal-cancer-statistics/
[2] https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/detection.html
[3] Comparing ColoAlert sensitivity with FITs (Gies et al. Gastroenterology 154/2018)

Read our EXCLUSIVE FREE report today and don't miss out on this incredible opportunity!

Find out more

Run by Professionals

.

Incredibly easy use means 98% patient satisfaction

A management team’s credentials is one of the key indicators investors should look for when determining how well a stock will perform.

Thankfully the Mainz BioMed management team, board and advisors tick all the right boxes.

They have a particularly impressive skill set when it comes to commercializing and monetizing medical diagnostics at some of the world’s most prominent medical companies.

CEO & Director Guido Baechler is a former molecular diagnostics executive for Roche’s leading global program management. And a 30-year veteran of leading life science companies.

Then there’s CFO William Caragol, who has 30 years of experience with growth-stage tech companies, including as Director for Greenbox POS, Worksport Ltd., and as former Chairman and CEO of PositiveID.

Joining them are COO Phillipp Freese and CSO and Director Moritz Eldends Ph.D., who co-led PharmGenomics, founded in 2008 and focused on developing innovative methodologies for the detection of genetic variants.

Hans Hekland, Alberto Libanori and Nicole Holden serve as Directors, each with decades of experience. Hekland is the co-founder of ColoAlert SA, while Libanori has authored over 20 peer-reviewed articles in journals including Advanced Materials, ACS Nano, Materials Today and Biosensors and Bioelectronics, and is the holder of two patents.

Mainz BioMed and ColoAlert are undoubtedly in good hands.

Huge market potential

Recent FDA guidance recommends colorectal cancer screening every three years for everyone over the age of 45, which translates to a market potential of over 52 million tests per year.[1]

ColoAlert is designed to be simple, easy, and non-invasive—and the hope is that approvals in other markets outside of the EU will allow its tests to help many millions more people detect early and save lives.

As a public company, they’re at the very beginning of what looks to be one of the most exciting stories in the biotech sector for years to come.

The company presents many reasons for bullish sentiment to prevail, in the belief it’s getting set to explode in the US market.

In addition to ColoAlert, Mainz BioMed is also in the early stages of developing a novel early detection pancreatic cancer screening test.

This is NOT the kind of opportunity that comes along often, nor is it one you want to miss out on.

NOW is the time to ACT!

[1] https://mainzbiomed.com/coloalert/#condition

To discover more about this money-spinning opportunity download the company deck today!

.

Company Info

Mainz BioMed (NASDAQ: MYNZ) develops market-ready molecular genetic diagnostic solutions for life-threatening conditions.

Exchange / Symbol
NASDAQ:MYNZ
Market Capitalization
$ (usd)
Current price
$ (usd)
Current mid price
$ (usd)
52 Week high price
$ (usd)
52 Week low price
$ (usd)

For details of this revenue-funded scalable investment opportunity please download the company deck.

IMPORTANT NOTICE AND DISCLAIMER

PAID ADVERTISEMENT

This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Publiko: Mainz Biomed PBL002 to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of fifty thousand US dollars to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.

CHANGES IN SHARE TRADING AND PRICE

Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.

NO OFFER TO SELL OR BUY SECURITIES

This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.

INFORMATION

Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.

This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.

NO FINANCIAL ADVICE

The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.

FORWARD LOOKING STATEMENTS

This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.

INDEMNIFICATION/RELEASE OF LIABILITY

By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.

TERMS OF USE AND DISCLAIMER

By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here https://www.valuethemarkets.com/terms-conditions/ and acknowledge that you have reviewed the Disclaimer found here https://www.valuethemarkets.com/disclaimer/. If you do not agree to the Terms of Use, please contact valuethemarkets.com to discontinue receiving future communications.

INTELLECTUAL PROPERTY

All trademarks used in this communication are the property of their respective trademark holders. Other than valuethemarkets.com, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than valuethemarkets.com.

AUTHORS: VALUETHEMARKETS

valuethemarkets.com and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of valuethemarkets.com, has been paid for the production of this piece by the company or companies mentioned above.